Compton John G. 4

What Happened

• John G. Compton, a director of 20/20 Biolabs, reported the automatic conversion of Series A-2 preferred stock into common stock on Feb 19, 2026. The filing shows the conversion resulted in the acquisition of 7,669 common shares at $0.00 and the corresponding disposition (conversion) of 7,669 derivative preferred shares.
• The conversion was triggered by the listing of the issuer’s common stock on the Nasdaq Capital Market. No cash was paid or received in the conversion.

Key Details

• Transaction date: 2026-02-19. Form 4 filed: 2026-02-23 (timely under Section 16 rules).
• Reported acquisition: 7,669 common shares at $0.00 per share (conversion). Reported disposition: 7,669 derivative securities (Series A-2 preferred) as part of the conversion.
• Shares owned after the transaction: not specified in the information provided in this summary.
• Footnote: F1 — All shares of Series A-2 preferred held by the reporting person were automatically converted into an equivalent number of common shares upon the Nasdaq listing; the Series A-2 preferred had no expiration date.

Context

• This was an automatic conversion of preferred into common stock due to the company’s Nasdaq listing — not a market purchase or sale. Such conversions change the holder’s share class but do not itself indicate a buy/sell decision by the insider.
• For investors, conversions can increase the number of outstanding common shares and change share class composition; they are routine corporate events tied to financing or listing terms rather than direct insider sentiment.